Analysts Offer Predictions for Medicus Pharma Q2 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Stock analysts at Brookline Capital Markets lifted their Q2 2026 earnings per share (EPS) estimates for shares of Medicus Pharma in a research note issued on Wednesday, May 20th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.16). The consensus estimate for Medicus Pharma’s current full-year earnings is ($0.51) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.36) EPS, FY2029 earnings at $0.73 EPS and FY2030 earnings at $1.26 EPS.

Several other analysts also recently issued reports on MDCX. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research note on Monday, April 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, April 10th. Finally, Roth Mkm began coverage on Medicus Pharma in a research note on Tuesday, April 21st. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medicus Pharma has a consensus rating of “Hold” and a consensus price target of $9.00.

Medicus Pharma Price Performance

MDCX opened at $0.30 on Monday. The business’s 50-day moving average price is $0.39 and its two-hundred day moving average price is $1.15. Medicus Pharma has a 1 year low of $0.25 and a 1 year high of $7.73. The company has a market capitalization of $17.00 million, a price-to-earnings ratio of -0.11 and a beta of -0.47.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.13).

Institutional Trading of Medicus Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in shares of Medicus Pharma in the fourth quarter valued at about $2,771,000. Private Advisor Group LLC increased its position in shares of Medicus Pharma by 36.8% in the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after acquiring an additional 64,560 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Medicus Pharma in the third quarter valued at about $532,000. Jane Street Group LLC acquired a new stake in shares of Medicus Pharma in the fourth quarter valued at about $92,000. Finally, Wilmington Savings Fund Society FSB increased its position in shares of Medicus Pharma by 100.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after acquiring an additional 25,622 shares during the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.